Date: 2011-09-06
Type of information: Development agreement
Compound: molecular companion diagnostic for a JAK2 inhibitor
Company: Qiagen (The Netherlands) Eli Lilly (USA)
Therapeutic area: Cancer - Oncology
Type agreement: development
manufacturing
production
commercialisation
Action mechanism:
Disease: myeloproliferative neoplasms
Details: Qiagen has entered into a partnership with Eli Lilly for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. This compound, a JAK2 inhibitor, targets the Janus kinase 2 (JAK2) gene, which has been shown to play a role in myeloproliferative neoplasms, a variety of blood cancers that cause blood cells to grow abnormally. Under the terms of the agreement, Qiagen will develop a new companion diagnostic test that will provide both qualitative and quantitative results for JAK2 V617F. The assay is intended to identify patients most likely to benefit from treatment with inhibitors of the pathway. The scope of the partnership includes development and use of the Qiagen JAK2 assay during clinical trials and also covers manufacturing and joint commercialization of the diagnostic product in parallel with the Lilly compound. Qiagen gained exclusive access to the JAK2 biomarker through an agreement with Ipsogen, a French company that is a pioneer in profiling and biomarkers for leukemia and other blood cancers. In June, Qiagen announced a proposal to fully acquire Ipsogen through a process that is under way.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
